<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Follow-on</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Eight biopharmas tap markets for $3.24B in early holiday rally</title>
      <description>
        <![CDATA[Christmas came early for a number of biopharma companies this year as eight companies collectively raised $3.24 billion in public offerings. Both Structure Therapeutics Inc. and Terns Pharmaceuticals Inc. announced upsized offerings of $650 million each, and Kymera Therapeutics Inc. raised $602 million, placing all three in the top 10 follow-on offerings of the year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726888</guid>
      <pubDate>Wed, 10 Dec 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726888-eight-biopharmas-tap-markets-for-324b-in-early-holiday-rally</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-dollar-sign-and-blue-circular-arrows.webp?t=1729544931" type="image/jpeg" medium="image" fileSize="126086">
        <media:title type="plain">Gold dollar sign and blue circular arrows</media:title>
      </media:content>
    </item>
    <item>
      <title>Merus raising $400M; petosemtamab scores in head and neck cancer</title>
      <description>
        <![CDATA[After shares climbed 36% on May 24 following the release of an American Society of Clinical Oncology abstract detailing an impressive phase II overall response rate in first-line head and neck cancer with bispecific antibody petosemtamab in combination with pembrolizumab, Merus NV is raising $400.2 million in an upsized follow-on offering.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709120</guid>
      <pubDate>Thu, 30 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709120-merus-raising-400m-petosemtamab-scores-in-head-and-neck-cancer</link>
    </item>
    <item>
      <title>COVID-19 crisis propels European biotech H1 2020 investing to $5B</title>
      <description>
        <![CDATA[DUBLIN – Even by any normal measure of European biotechnology investment, the first two quarters of 2020 were memorable. If it maintains the present momentum, Europe’s drug development sector is on course for a record-breaking year, having already raised $5.034 billion in publicly disclosed equity investments. That puts it well ahead of any other year – the sector edged to a new high in 2019 when it raised $7.739 billion over the full 12 months  – but, of course, comparisons with any other year seem irrelevant. This year is like no other. The COVID-19 pandemic has changed everything.]]>
      </description>
      <guid>http://www.bioworld.com/articles/436255</guid>
      <pubDate>Mon, 06 Jul 2020 14:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436255-covid-19-crisis-propels-european-biotech-h1-2020-investing-to-5b</link>
    </item>
    <item>
      <title>Dollars double in May as Sanofi, Moderna, Apellis, Atea finance COVID-19 work</title>
      <description>
        <![CDATA[Money raised through biopharma financings so far in 2020 is double the amount raised within the same timeframe of 2019, partly due to two large financings completed in May by Sanofi SA, which is working on candidates to treat or prevent COVID-19, the disease caused by the SARS-CoV-2 virus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435596</guid>
      <pubDate>Fri, 05 Jun 2020 12:30:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435596-dollars-double-in-may-as-sanofi-moderna-apellis-atea-finance-covid-19-work</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Coronavirus-stock-market.webp?t=1604529782" type="image/png" medium="image" fileSize="461634">
        <media:title type="plain">Coronavirus and stock charts</media:title>
      </media:content>
    </item>
    <item>
      <title>Moderna tops public biopharma raises with $1.34B to help fund its COVID-19 vaccine</title>
      <description>
        <![CDATA[Representing the highest amount ever raised by a public biopharma company on a U.S. exchange, Moderna Inc. priced a $1.34 billion follow-on offering to help fund worldwide manufacturing and distribution of its mRNA-1273 vaccine for COVID-19.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435211</guid>
      <pubDate>Tue, 19 May 2020 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435211-moderna-tops-public-biopharma-raises-with-134b-to-help-fund-its-covid-19-vaccine</link>
    </item>
    <item>
      <title>April bounces back; 57% of grants for COVID-19</title>
      <description>
        <![CDATA[Despite a global pandemic that is wreaking havoc on the overall economy, biopharma financings and grants during the month of April have shown solid numbers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/434797</guid>
      <pubDate>Fri, 01 May 2020 12:25:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/434797-april-bounces-back-57-of-grants-for-covid-19</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Money-coronavirus.webp?t=1588371950" type="image/png" medium="image" fileSize="556119">
        <media:title type="plain">$100 bill, portrait covered with mask </media:title>
      </media:content>
    </item>
    <item>
      <title>Lukewarm start to year weighs heavily on sector’s performance</title>
      <description>
        <![CDATA[Biotech investors had every reason to feel bullish heading into the new decade. The sector had turned around in 2019 and was riding a wave of a very strong fourth-quarter performance, with the BioWorld Biopharmaceutical Index closing up 14% for the year after being underwater from April through to September. Unfortunately, those great expectations were quickly erased during J.P. Morgan Healthcare conference week (Jan. 10 – Jan. 17), which turned out to be a very low-key affair absent of any blockbuster M&A revelations. As a result, confidence has now given way to concerns about the prospects for biopharmaceutical companies going forward, particularly as unfavorable political rhetoric on drug pricing will certainly be dialed up during this election year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432805</guid>
      <pubDate>Mon, 03 Feb 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432805-lukewarm-start-to-year-weighs-heavily-on-sectors-performance</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Money-financial-thermometer.webp?t=1588783202" type="image/png" medium="image" fileSize="353105">
        <media:title type="plain">Dollar sign thermometer</media:title>
      </media:content>
    </item>
    <item>
      <title>Notes offerings place 2019 financings at a three-year high, as volumes steadily increase</title>
      <description>
        <![CDATA[Med-tech companies brought in more money than each of the last two years in every type of financing, aside from private placements, with about 11% of the funds flowing into digital health companies. In total, the industry raised $40.67 billion, an increase of 98% over 2018, which logged $20.6 billion and was more in line with the $19.4 billion raised in 2017.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432338</guid>
      <pubDate>Fri, 10 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432338-notes-offerings-place-2019-financings-at-a-three-year-high-as-volumes-steadily-increase</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/business-data-dollar.webp?t=1588793660" type="image/png" medium="image" fileSize="430626">
        <media:title type="plain">Business, data, dollars illustration</media:title>
      </media:content>
    </item>
  </channel>
</rss>
